The Journal of Experimental Medicine
StemCell Technologies
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 18 April 2005. doi:10.1084/jem.20041385
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 201, Number 8, 1307-1318
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Broxmeyer, H. E.
Right arrow Articles by Srour, E. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Broxmeyer, H. E.
Right arrow Articles by Srour, E. F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

Hal E. Broxmeyer1,2,4,6, Christie M. Orschell2, D. Wade Clapp1,3,5, Giao Hangoc1,4,6, Scott Cooper1,4,6, P. Artur Plett2, W. Conrad Liles7, Xiaxin Li3,5, Barbara Graham-Evans1,4,6, Timothy B. Campbell1,4,6, Gary Calandra8, Gary Bridger8, David C. Dale7, and Edward F. Srour1,2,3,5

1 Department of Microbiology and Immunology, Indiana University School of Medicine
2 Department of Medicine, Indiana University School of Medicine
3 Department of Pediatrics, Indiana University School of Medicine
4 Walther Oncology Center, Indiana University School of Medicine
5 Wells Center for Pediatric Research, Indiana University School of Medicine
6 Walther Cancer Institute, Indianapolis, IN 46202
7 Department of Medicine, University of Washington, Seattle, WA 98195
8 AnorMed Inc., Langley, British Columbia, Canada, V2Y 1N5

CORRESPONDENCE Hal E. Broxmeyer: hbroxmey{at}iupui.edu

Improving approaches for hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) mobilization is clinically important because increased numbers of these cells are needed for enhanced transplantation. Chemokine stromal cell derived factor-1 (also known as CXCL12) is believed to be involved in retention of HSCs and HPCs in bone marrow. AMD3100, a selective antagonist of CXCL12 that binds to its receptor, CXCR4, was evaluated in murine and human systems for mobilizing capacity, alone and in combination with granulocyte colony-stimulating factor (G-CSF). AMD3100 induced rapid mobilization of mouse and human HPCs and synergistically augmented G-CSF–induced mobilization of HPCs. AMD3100 also mobilized murine long-term repopulating (LTR) cells that engrafted primary and secondary lethally-irradiated mice, and human CD34+ cells that can repopulate nonobese diabetic-severe combined immunodeficiency (SCID) mice. AMD3100 synergized with G-CSF to mobilize murine LTR cells and human SCID repopulating cells (SRCs). Human CD34+ cells isolated after treatment with G-CSF plus AMD3100 expressed a phenotype that was characteristic of highly engrafting mouse HSCs. Synergy of AMD3100 and G-CSF in mobilization was due to enhanced numbers and perhaps other characteristics of the mobilized cells. These results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clinical potential of AMD3100 for HSC mobilization.


Abbreviations used: BFU-E, burst-forming unit–erythroid; Epo, erythropoietin; GEMM, granulocyte erythroid macrophage, megakaryocyte; GM, granulocyte macrophage; HPC, hematopoietic progenitor cell; HSC, hematopoietic stem cell; LDMNC, low-density mononuclear cell; LTR, long-term repopulating; rhu, recombinant human; NOD, nonobese diabetic; SDF, stromal cell–derived factor; SRC, SCID repopulating cell; TMCR, long-term marrow competitive repopulating; VLA, very late antigen.

C.M. Orschell and D.W. Clapp contributed equally to this work.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS